Shilpa Biologicals Commissions Integrated ADC GMP Manufacturing Facility

Shilpa Biologicals Private Limited, a material subsidiary of Shilpa Medicare Ltd, has commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP Manufacturing Facility. This facility is designed to meet global regulatory standards and is now operational, with GMP qualification protocols underway. It represents a significant expansion of Shilpa Medicare's expertise in highly potent compound manufacturing, offering integrated end-to-end ADC Drug Substance development and manufacturing services, including payload synthesis, linker development, monoclonal antibody production, ADC conjugation, and purification. This positions Shilpa as a cost-competitive CDMO partner for global pharmaceutical and biotech companies, particularly in the oncology segment.